BERGEN, Norway, Jan. 29, 2018 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing bemcentinib as a potential cornerstone therapy for multiple cancer indications, today announced the presentation ...
more»